<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621933</url>
  </required_header>
  <id_info>
    <org_study_id>MA-Zymar-08-001</org_study_id>
    <nct_id>NCT00621933</nct_id>
  </id_info>
  <brief_title>Surveillance of Ocular Surface Flora (SURFACE)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Topical fluoroquinolones (FQs) have achieved widespread use in ophthalmology for both the
      treatment and prophylaxis of ocular infections. The present study is set to determine the
      bacteria present on the ocular surface in patients at the time of cataract surgery and to
      assess the rate of resistance of ocular isolates to commonly used topical antibiotics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Eyelid</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of staphylococcus epidermidis species susceptible and resistant to oxacillin on the eyelid. The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus epidermidis, the oxacillin MIC breakpoints were &lt;= 0.25 ug/ml (susceptible) and &gt;= 0.50 ug/ml (resistant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Conjunctiva</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of staphylococcus epidermidis species susceptible and resistant to oxacillin on the conjunctiva . The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus epidermidis, the oxacillin MIC breakpoints were &lt;= 0.25 ug/ml (susceptible) and &gt;= 0.50 ug/ml (resistant).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Eyelid</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of staphylococcus aureus species susceptible and resistant to oxacillin on the eyelid. The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus aureus, the oxacillin MIC breakpoints were &lt;= 2 ug/ml (susceptible) and &gt;= 4 ug/ml (resistant).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Conjunctiva</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of staphylococcus aureus species susceptible and resistant to oxacillin on the conjunctiva. The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus aureus, the oxacillin MIC breakpoints were &lt;= 2 ug/ml (susceptible) and &gt;= 4 ug/ml (resistant).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">399</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>All Patients Receiving Cataract Surgery</arm_group_label>
    <description>All Patients Receiving Cataract Surgery</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Culture Swabs of the conjunctiva and eyelids
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cataract Surgery Patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo cataract surgery

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  NSAID in the eye to be swabbed within the past 30 days

          -  Topical anesthetic, topical antibiotic or antiseptic, or dilating drops in the eye to
             the swabbed within the past 7 days

          -  Over-the-counter artificial tear drops or astringent /redness reliever drops (e.g.,
             Visine®, Clear eyes® in the eye to be swabbed on the day of trial

          -  History of conjunctivitis or any ocular infection within the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>October 17, 2011</results_first_submitted>
  <results_first_submitted_qc>July 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2012</results_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a culture swab study at a single time-point. No medications were administered and patients were not followed beyond the initial culture.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>All patients receiving cataract surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>All patients receiving cataract surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="399"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 50 and 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 60 and 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 70 and 79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 80 and 89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 90 and 99 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Eyelid</title>
        <description>Percentage of staphylococcus epidermidis species susceptible and resistant to oxacillin on the eyelid. The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus epidermidis, the oxacillin MIC breakpoints were &lt;= 0.25 ug/ml (susceptible) and &gt;= 0.50 ug/ml (resistant).</description>
        <time_frame>Baseline</time_frame>
        <population>ITT population. All patients with cultures performed of the ocular surface.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients receiving cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Eyelid</title>
          <description>Percentage of staphylococcus epidermidis species susceptible and resistant to oxacillin on the eyelid. The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus epidermidis, the oxacillin MIC breakpoints were &lt;= 0.25 ug/ml (susceptible) and &gt;= 0.50 ug/ml (resistant).</description>
          <population>ITT population. All patients with cultures performed of the ocular surface.</population>
          <units>Percentage of Species</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Species Oxacillin-Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Species Oxacillin-Resistant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Conjunctiva</title>
        <description>Percentage of staphylococcus epidermidis species susceptible and resistant to oxacillin on the conjunctiva . The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus epidermidis, the oxacillin MIC breakpoints were &lt;= 0.25 ug/ml (susceptible) and &gt;= 0.50 ug/ml (resistant).</description>
        <time_frame>Baseline</time_frame>
        <population>ITT population. All patients with cultures performed of the ocular surface.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients receiving cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Staphylococcus Epidermidis Species Susceptible and Resistant to Oxacillin on the Conjunctiva</title>
          <description>Percentage of staphylococcus epidermidis species susceptible and resistant to oxacillin on the conjunctiva . The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus epidermidis, the oxacillin MIC breakpoints were &lt;= 0.25 ug/ml (susceptible) and &gt;= 0.50 ug/ml (resistant).</description>
          <population>ITT population. All patients with cultures performed of the ocular surface.</population>
          <units>Percentage of Species</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Species Oxacillin-Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Species Oxacillin-Resistant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Eyelid</title>
        <description>Percentage of staphylococcus aureus species susceptible and resistant to oxacillin on the eyelid. The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus aureus, the oxacillin MIC breakpoints were &lt;= 2 ug/ml (susceptible) and &gt;= 4 ug/ml (resistant).</description>
        <time_frame>Baseline</time_frame>
        <population>ITT population. All patients with cultures performed of the ocular surface.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients receiving cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Eyelid</title>
          <description>Percentage of staphylococcus aureus species susceptible and resistant to oxacillin on the eyelid. The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus aureus, the oxacillin MIC breakpoints were &lt;= 2 ug/ml (susceptible) and &gt;= 4 ug/ml (resistant).</description>
          <population>ITT population. All patients with cultures performed of the ocular surface.</population>
          <units>Percentage of Species</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Species Oxacillin-Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Species Oxacillin-Resistant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Conjunctiva</title>
        <description>Percentage of staphylococcus aureus species susceptible and resistant to oxacillin on the conjunctiva. The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus aureus, the oxacillin MIC breakpoints were &lt;= 2 ug/ml (susceptible) and &gt;= 4 ug/ml (resistant).</description>
        <time_frame>Baseline</time_frame>
        <population>ITT population. All patients with cultures performed of the ocular surface.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients receiving cataract surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Staphylococcus Aureus Species Susceptible and Resistant to Oxacillin on the Conjunctiva</title>
          <description>Percentage of staphylococcus aureus species susceptible and resistant to oxacillin on the conjunctiva. The minimum inhibitory concentrations (MIC) of each species were determined and compared to oxacillin MIC breakpoints. MIC is the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism after incubation. For Staphylococcus aureus, the oxacillin MIC breakpoints were &lt;= 2 ug/ml (susceptible) and &gt;= 4 ug/ml (resistant).</description>
          <population>ITT population. All patients with cultures performed of the ocular surface.</population>
          <units>Percentage of Species</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Species Oxacillin-Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Species Oxacillin-Resistant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious adverse events and adverse events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>All patients receiving cataract surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Medical Affairs</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

